Transaction in Own Shares

Summary by AI ^BETAClose X

CVS Group plc has announced the purchase of 30,119 ordinary shares on January 9, 2026, as part of its share buyback program, with prices ranging from 1,324.00 pence to 1,360.00 pence per share, averaging 1,344.63 pence. These shares will be cancelled, reducing the total number of issued ordinary shares to 70,551,512, with no shares held in treasury. Since the program's inception, CVS has repurchased a total of 1,189,271 ordinary shares at a weighted average price of 1,231.92 pence.

Disclaimer*

CVS Group plc

12 January 2026

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 09 January 2026 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase:	09/01/2026
Aggregate number of Ordinary Shares purchased:	30,119
Lowest price paid per share (GBp):	1,324.00
Highest price paid per share (GBp):	1,360.00
Volume weighted average price paid per share (GBp):	1,344.63

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,551,512 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,551,512 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 1,189,271 Ordinary Shares in aggregate at a weighted average price of 1,231.92 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
231	1324	09/01/2026 08:08:13	1367544040526662	XLON
66	1324	09/01/2026 08:09:54	1367544040527466	XLON
553	1330	09/01/2026 08:12:24	1367544040527993	XLON
600	1330	09/01/2026 08:19:13	1367544040529841	XLON
387	1330	09/01/2026 08:27:43	1367544040531501	XLON
49	1330	09/01/2026 08:27:43	1367544040531502	XLON
320	1330	09/01/2026 08:27:44	1367544040531519	XLON
797	1338	09/01/2026 08:52:39	1367544040534919	XLON
1390	1338	09/01/2026 08:52:47	1367544040534928	XLON
1390	1338	09/01/2026 08:58:18	1367544040535665	XLON
725	1338	09/01/2026 08:59:31	1367544040535843	XLON
148	1340	09/01/2026 09:04:38	1367544040537216	XLON
1158	1338	09/01/2026 09:20:21	1367544040539210	XLON
180	1338	09/01/2026 09:20:21	1367544040539212	XLON
66	1336	09/01/2026 09:27:21	1367544040540037	XLON
4	1336	09/01/2026 10:05:18	1367544040545512	XLON
356	1336	09/01/2026 10:07:20	1367544040545755	XLON
424	1334	09/01/2026 10:07:20	1367544040545769	XLON
121	1334	09/01/2026 10:07:26	1367544040545779	XLON
9	1334	09/01/2026 10:07:26	1367544040545780	XLON
260	1338	09/01/2026 11:01:15	1367544040551733	XLON
66	1338	09/01/2026 11:02:45	1367544040551861	XLON
823	1336	09/01/2026 11:11:07	1367544040552555	XLON
204	1334	09/01/2026 11:14:33	1367544040552735	XLON
190	1334	09/01/2026 11:14:33	1367544040552736	XLON
141	1332	09/01/2026 11:18:00	1367544040552913	XLON
154	1328	09/01/2026 11:32:45	1367544040553839	XLON
159	1334	09/01/2026 12:02:04	1367544040555609	XLON
84	1332	09/01/2026 12:13:33	1367544040557112	XLON
66	1332	09/01/2026 12:18:03	1367544040557569	XLON
125	1332	09/01/2026 12:18:04	1367544040557570	XLON
242	1336	09/01/2026 12:29:55	1367544040558491	XLON
1272	1340	09/01/2026 12:36:08	1367544040559021	XLON
700	1348	09/01/2026 13:07:35	1367544040562181	XLON
200	1348	09/01/2026 13:07:35	1367544040562187	XLON
847	1348	09/01/2026 13:10:54	1367544040562540	XLON
351	1348	09/01/2026 13:10:54	1367544040562541	XLON
1185	1348	09/01/2026 13:22:08	1367544040563729	XLON
895	1350	09/01/2026 13:36:22	1367544040565981	XLON
430	1350	09/01/2026 13:45:38	1367544040567100	XLON
150	1350	09/01/2026 13:45:38	1367544040567101	XLON
10000	1350	09/01/2026 13:49:16	1367544040567707	XLON
100	1360	09/01/2026 15:50:22	1367544040590331	XLON
214	1360	09/01/2026 16:03:38	1367544040592690	XLON
683	1360	09/01/2026 16:03:38	1367544040592693	XLON
186	1360	09/01/2026 16:03:38	1367544040592689	XLON
186	1360	09/01/2026 16:03:38	1367544040592694	XLON
12	1360	09/01/2026 16:03:38	1367544040592695	XLON
174	1360	09/01/2026 16:03:38	1367544040592696	XLON
186	1360	09/01/2026 16:03:38	1367544040592697	XLON
186	1360	09/01/2026 16:03:38	1367544040592698	XLON
186	1360	09/01/2026 16:03:38	1367544040592699	XLON
186	1360	09/01/2026 16:03:38	1367544040592700	XLON
186	1360	09/01/2026 16:03:38	1367544040592701	XLON
116	1360	09/01/2026 16:05:17	1367544040592928	XLON

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR) cvsg@camarco.co.uk

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END